Physician profile
Imran Dosani
NPI 1215142401
$633.92
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $99.00 · 2021: $239 · 2022: $18.96 · 2023: $42.23 · 2024: $41.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.39 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.39 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $205.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $137.41 | 2020-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $118.81 | 2019 | |
| Fresenius USA Marketing, INC. | $40.65 | 2021-2023 | Velphoro |
| Lundbeck LLC | $40.00 | 2019 | |
| Amgen INC. | $34.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.34 | 2021-2022 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Dosani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.